Sunshine Biopharma Inc. (NASDAQ: SBFM) said its mRNA-based cancer therapy program, K1.1, has delivered encouraging preclinical results, with the company’s shares rising 8.77% to $1.24 on Tuesday.
The Miami-based biotech’s mRNA K1.1 program uses lipid nanoparticles to deliver genetic material targeting a tumor suppressor gene frequently mutated in hepatocellular carcinoma, non-small cell lung cancer and pancreatic cancer. In animal studies, the therapy demonstrated single-agent tumor suppression activity across multiple hepatocellular carcinoma models. Systemic administration restored the targeted tumor suppressor in liver tumors engrafted in at least two orthotopic mouse models, with dose-dependent effects observed.
Laboratory experiments further showed antiproliferative activity across several non-small cell lung cancer cell lines, according to the company. Sunshine Biopharma plans to combine mRNA K1.1 with a cancer vaccine targeting associated antigens in non-small cell lung cancer, aiming to convert immunologically inactive tumors into active targets for treatment.
Beyond its oncology pipeline, Sunshine Biopharma generates revenue from the commercialization of 60 prescription generic drugs in Canada. The company expects to launch approximately 12 additional products by the end of 2026. It is also developing a PLpro protease inhibitor for potential use against SARS coronavirus infections.
Steve Slilaty, chief executive officer, said the mRNA K1.1 program continues to deliver encouraging results that validate the company’s strategy of restoring tumor suppressors in cancer treatment.
Sunshine Biopharma’s shares were trading at $1.24, up $0.10, or 8.77%, at the close of U.S. markets on August 26, 2026.
